Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI response correctly identifies atorvastatin's muscle-related adverse effects, liver enzyme changes, and drug interactions as key safety concerns, aligning with the label. It largely omits or misattributes cardiovascular or bradycardia-related content, which is not supported by the label.
Category Scores
Accurate Statements
In routine prescribing and safety profiles, atorvastatin's more well-known concerns are muscle-related effects.
Adverse Reactions (6) lists rhabdomyolysis and myopathy.
In routine prescribing and safety profiles, atorvastatin's more well-known concerns are liver enzyme changes.
Adverse Reactions (6) lists liver enzyme abnormalities.
In routine prescribing and safety profiles, atorvastatin's more well-known concerns are interactions with other drugs.
Drug Interactions (7) notes increased risk of myopathy with concomitant drugs; Patient Counseling (17) references avoiding concomitant substances and informing prescribers.
Unsupported Statements
Atorvastatin is not typically known for causing slow heart rate (bradycardia) as a common or expected side effect.
No bradycardia mention in Adverse Reactions (6) or Patient Counseling (17); label focuses on myopathy, liver enzyme abnormalities, and drug interactions.
Atorvastatin is more likely to contribute to heart-related issues indirectly if it interacts with other medicines that affect heart rate.
Label discussions focus on myopathy and liver enzyme abnormalities with interactions; no heart-rate related adverse effects described.
Atorvastatin is more likely to contribute to heart-related issues indirectly if it causes muscle injury (rare), which can lead to complications.
Label includes myopathy/rhabdomyolysis but does not describe heart-related complications from muscle injury.
A slow heart rate can happen from many causes unrelated to atorvastatin, including thyroid problems, electrolyte imbalances, heart rhythm disorders, and age-related conduction changes.
No bradycardia etiologies described in provided sections.
If your heart rate is consistently low for you or you feel symptoms, check your pulse and note the time and symptoms.
No patient self-monitoring guidance for bradycardia in provided sections.
Contact the clinician who prescribed atorvastatin.
No explicit instruction to contact prescriber in provided sections.
Your prescriber may want an ECG and basic labs (for example, thyroid and electrolytes) to confirm the cause.
No such guidance in the provided sections.
Get emergency care if slow heart rate comes with fainting or severe dizziness.
No emergency criteria for bradycardia described in provided sections.
Get emergency care if slow heart rate comes with chest pain.
No emergency bradycardia criteria described in provided sections.
Get emergency care if slow heart rate comes with shortness of breath.
No emergency bradycardia criteria described in provided sections.
Get emergency care if slow heart rate comes with confusion or inability to stay awake.
No emergency bradycardia criteria described in provided sections.
Contradictions
Important Omissions
No bradycardia-related adverse effects or cardiovascular events discussed in Adverse Reactions (6) or Patient Counseling (17).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label emphasizes myopathy/rhabdomyolysis and liver enzyme abnormalities with potential drug interactions; no labeled bradycardia or cardiovascular risk described.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue